L1 SAQ - Intro

Name two major developments in the pharmaceutical industry related to cancer therapy.

What are the hallmarks of cancer?

What are the basic processes of the cell cycle?

What is the major protein of erythrocytes?

What is sickle cell anemia?

What did Linus Pauling discover about sickle cell anemia hemoglobin?

What is the role of Cdc7 kinase in DNA replication?

How do Cdc7 inhibitors work in cancer therapy?

What is molecular medicine?

What are the general concepts of cancers?

Which disease besides cancer has small-molecule kinase inhibitors been approved for?

How many small-molecule kinase inhibitors (SMKIs) are currently approved by the FDA?

Approximately what percentage of the human kinome is represented by the targets of approved kinase inhibitors and the novel kinases being explored?

What are some trends in kinase inhibitor design mentioned in the article?

Which regulatory agency has approved the highest number of small-molecule kinase inhibitors (SMKIs)?

Which kinase inhibitor has been approved for a non-oncology indication?

Which kinase family was the first to have an agent targeting it approved?

Which regulatory agency has approved the highest number of monoclonal antibodies?

Which major group of protein kinases do atypical protein kinases belong to?

Which natural compound was pursued as a potential kinase inhibitor despite having poor selectivity?

What was the first kinase inhibitor to reach the market in the United States?

Which kinase inhibitor is perceived as a pivotal landmark in the development of kinase inhibitors?

What is the main purpose of using CenterWatch as a resource for obtaining information on new kinase inhibitors entering clinical trials?

Which of the following is NOT mentioned as a resource for obtaining information on the molecular targets of new kinase inhibitors entering clinical trials?

What is the advantage of the methods used to create the dataset of kinase inhibitors in clinical trials?

What is the proportion of FDA-approved kinase inhibitors that are small molecule kinase inhibitors (SMKIs)?

Which gene families are targeted by tirbanibulin?

Which mutations are considered sensitizing mutations associated with EGFR kinase domain?

Which kinase inhibitors are approved by the FDA for the treatment of NSCLC?

Which gene rearrangement is identified in approximately 5% of NSCLC cases?

Which compound was discovered through a phenotypic screen using BCR-ABL-transformed cell lines?

What is the function of the myr pocket in the ABL kinase domain?

Which compound can induce an auto-inhibited conformation of the ABL-T315I mutant?

What is the primary end point of the phase III trial involving asciminib?

Which compound is expected to have a regulatory submission in 2021?

Which compound is among the most potent and specific ABL kinase inhibitors known to date?

Which group of protein kinases are primarily targeted by the FDA-approved small-molecule kinase inhibitors (SMKIs)?

Which family of receptor tyrosine kinases (RTKs) is the most targeted by FDA-approved SMKIs?

How many FDA-approved SMKIs primarily target proteins within the TK group?

What is the most common indication for FDA-approved SMKIs and monoclonal antibodies (mAbs) that target kinases?

Which group of kinases is the most targeted by FDA-approved SMKIs?

Which family of RTKs has the most FDA-approved SMKIs and mAbs targeting them?

Which kinase group has the highest percentage of it targeted by FDA-approved SMKIs?

What percentage of FDA-approved SMKIs have oncology indications?